NCT07728604

Brief Summary

This randomized controlled study aimed to evaluate the effect of digital follow-up supported patient education on immunosuppressive medication adherence and quality of life in adult liver transplant recipients. Participants in both groups received standard discharge education. The intervention group additionally received structured digital follow-up messages for 12 weeks, while the control group received standard care only. Medication adherence and quality of life were assessed before and after the intervention using validated questionnaires.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 23, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2026

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 22, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 27, 2026

Completed
Last Updated

July 27, 2026

Status Verified

January 1, 2026

Enrollment Period

5 months

First QC Date

July 22, 2026

Last Update Submit

July 22, 2026

Conditions

Liver TransplantationMedication Adherence

Keywords

Liver transplantationImmunosuppressive medicationMedication adherenceDigital patient educationDigital follow-upQuality of lifeRandomized controlled trialNursing intervention

Outcome Measures

Primary Outcomes (1)

  • Immunosuppressive Medication Adherence

    Immunosuppressive medication adherence was assessed using the Immunosuppressive Medication Adherence Scale used in this study.

    Baseline and 12 weeks

Secondary Outcomes (1)

  • Chronic Liver Disease Quality of Life Score (CLDQ 2.0)

    Baseline and 12 weeks

Study Arms (2)

Digital Education Group

EXPERIMENTAL

Participants received standard discharge education plus structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life.

Behavioral: Digital Follow-up Supported Patient Education

Control Group

ACTIVE COMPARATOR

articipants received standard discharge education and routine follow-up care without additional digital follow-up messages.

Other: Standard Care

Interventions

Digital Follow-up Supported Patient EducationBEHAVIORAL

Participants received standard discharge education followed by structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life.

Digital Education Group
Standard CareOTHER

Participants received routine discharge education and standard follow-up care. No additional digital follow-up messages or educational reminders were provided during the study period.

Control Group

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older.
  • Having undergone liver transplantation.
  • Currently receiving immunosuppressive therapy after liver transplantation.
  • Ability to read and write in Turkish.
  • Ability to use a smartphone to receive and follow digital messages.
  • Willingness to participate voluntarily in the study.
  • Provision of written informed consent.

You may not qualify if:

  • Experiencing an acute rejection episode during the study period.
  • Presence of cognitive, psychiatric, or communication problems that would interfere with participation in the study.
  • Inability to regularly follow digital messages.
  • Difficulty reading and understanding Turkish.
  • Inability to maintain communication throughout the study period.
  • Refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Acibadem İzmir Kent Hospital

Izmir, 35620, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Medication Adherence

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Patient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Cansu Yıldız

    İzmir Tınaztepe University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The study was conducted as a single-blind randomized controlled trial. The statistician/outcome assessor was blinded to group allocation during data analysis. Participants and the investigator providing the intervention were not blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 22, 2026

First Posted

July 27, 2026

Study Start

January 23, 2026

Primary Completion

June 20, 2026

Study Completion

June 20, 2026

Last Updated

July 27, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to participant confidentiality and institutional policies.

Locations

TU(1)